Impact of alginate-producing Pseudomonas aeruginosa on alveolar macrophage apoptotic cell clearance

Charlie A McCaslin1, Daniela N Petrusca2, Christophe Poirier2

  • 1Department of Pediatrics, Pediatric Pulmonology, Indiana University Purdue University Indianapolis, Indianapolis, IN.

Insights

Pseudomonas aeruginosa alginate inhibits macrophage clearance of apoptotic cells, contributing to cystic fibrosis lung inflammation. Alginate lyase may offer a therapeutic approach.

Area of Science:

  • Immunology
  • Microbiology
  • Pulmonary Medicine

Background:

  • Pseudomonas aeruginosa infection is central to cystic fibrosis lung disease.
  • During chronic infection, P. aeruginosa reduces virulence, often overproducing alginate.
  • The effect of alginate on macrophage efferocytosis (clearance of apoptotic cells) is unknown.

Purpose of the Study:

  • To investigate if alginate produced by mucoid P. aeruginosa inhibits macrophage efferocytosis.
  • To determine if alginate alone is sufficient to impair efferocytosis.
  • To explore alginate lyase as a potential therapeutic.

Main Methods:

  • In vitro exposure of rat alveolar or human THP-1 derived macrophages to alginate or mucoid P. aeruginosa.
  • Challenge with apoptotic human Jurkat T-lymphocytes.
  • Testing alginate purity and alginate lyase activity.

Main Results:

  • Alginate dose- and time-dependently inhibited macrophage efferocytosis.
  • Lipopolysaccharide (LPS) contamination augmented this inhibition.
  • Mucoid P. aeruginosa significantly inhibited efferocytosis; alginate lyase partially restored it.

Conclusions:

  • Alginate contributes to P. aeruginosa's immune evasion by inhibiting efferocytosis.
  • Alginate's synergy with LPS may drive chronic airway inflammation in cystic fibrosis.
  • Alginate lyase presents a potential therapeutic strategy for P. aeruginosa-related lung diseases.